Pharma

Your Article Summary

See Latest Articles

Human genome sciences to host november 2nd conference call to discuss top-line results from second phase 3 trial of benlysta (belimumab) in systemic lupus erythematosus
Human Genome Sciences, 10/16/09

Human Genome Sciences, Inc. announced that it expects to have top–line 52–week results available on Monday, November 2nd, from BLISS–76, the second of two pivotal Phase 3 clinical trials of BENLYSTA (belimumab) in systemic lupus erythematosus (SLE).

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/17/09

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09

 See all of Drug Trials